Expression of therapeutic targets in Ewing sarcoma family tumors

Human Pathology

Volumn 43, Issue 7, 2012, Pages 1077-1083

  Ahmed, Atif A ^a   Sherman, Ashley K ^a   Pawel, Bruce R ^b,c  

^a CHILDREN S MERCY HOSPITAL   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Ewing sarcoma; Immunohistochemistry; Therapeutic markers

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; RNA BINDING PROTEIN EWS; VASCULOTROPIN;

ADOLESCENT; ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CHILD; EWING SARCOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRESCHOOL CHILD; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SCHOOL CHILD; TUMOR LOCALIZATION;

ADOLESCENT; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; INFANT, NEWBORN; NF-KAPPA B; PHOSPHORYLATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT; SARCOMA, EWING; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84862572950     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2011.09.001     Document Type: Article

References (38)

1. Paulussen M, Fröhlich B, Jürgens H. Ewing tumor: incidence, prognosis and treatment options. Paediatr Drugs 2001;3:899-913.
2. Thacker MM, Temple HT, Scully SP. Current treatment for Ewing's sarcoma. Expert Rev Anticancer Ther 2005;5:319-31.
3. Ludwig JA. Ewing sarcoma: historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future. Curr Opin Oncol 2008;20:412-8.
4. Seddon BM, Whelan JS. Emerging chemotherapeutic strategies and the role of treatment stratification in Ewing sarcoma. Paediatr Drugs 2008;10:93-105.
5. Steven Grant S. Cotargeting survival signaling pathways in cancer. J Clin Invest 2008;118:3003-6.
6. Vojtěchová M, Turečková J, Kučerová D, et al. Regulation of mTORC1 signaling by Src kinase activity is Akt1-independent in RSV-transformed cells. Neoplasia 2008;10:99-107.
7. Carnero A. The PKB/AKT pathway in cancer. Curr Pharm Des 2010;16:34-44.
8. Mita MM, Mita A, Rowinsky EK. The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Cancer Biol Therapy 2003;2(Suppl 1):S169-77.
9. Okuno S. Mammalian target of rapamycin inhibitors in sarcomas. Curr Opin Oncol 2006;18:360-2.
10. Shin I, Edl J, Biswas S, et al. Proapoptotic activity of cell-permeable anti-Akt single-chain antibodies. Cancer Res 2005;65:2815-24.
11. Pratilas CA, Solit DB. Therapeutic strategies for targeting BRAF in human cancer. Rev Recent Clin Trials 2007;2:121-34.
12. Niault TS, Baccarini M. Targets of Raf in tumorigenesis. Carcinogenesis 2010;31:1165-74.
13. Niculescu-Duvaz I, Roman E, Whittaker SR, et al. Novel inhibitors of the v-raf murine sarcoma viral oncogene homologue B1 (BRAF) based on a 2,6-disubstituted pyrazine scaffold. J Med Chem 2008;51:3261-74.
14. Iyer R, Fetterly G, Lugade A, et al. Sorafenib: a clinical and pharmacologic review. Expert Opin Pharmacother 2010;11:1943-55.
15. Staudt LM. Oncogenic activation of NF-kappaB. Cold Spring Harb Perspect Biol 2010;2:a000109.
16. Izzo JG, Malhotra U, Wu TT, et al. Association of activated transcription factor nuclear factor kappa b with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol 2006;24:748-54.
17. Huang L, Chen CH. Proteasome regulators: activators and inhibitors. Curr Med Chem 2009;16:931-9.
18. Einsele H. Bortezomib. Recent Results Cancer Res 2010;184:173-87.
19. Holmes DI, Zachary I. The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease. Genome Biol 2005;6:209.
20. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002;29(6 Suppl 16):10-4.
21. Shinkaruk S, Bayle M, Laïn G, et al. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy. Curr Med Chem Anticancer Agents 2003;3:95-117.
22. Krishnan K, Bruce B, Hewitt S, Thomas D, Khanna C, Helman LJ. Ezrin mediates growth and survival in Ewing's sarcoma through the AKT/mTOR, but not the MAPK, signaling pathway. Clin Exp Metastasis 2006;23:227-36.
23. Hotfilder M, Sondermann P, Senss A, et al. PI3K/AKT is involved in mediating survival signals that rescue Ewing tumour cells from fibroblast growth factor 2-induced cell death. Br J Cancer 2005;92:705-10.
24. Mateo-Lozano S, Tirado OM, Notario V. Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation. Oncogene 2003;22:9282-7.
25. Lipskar AM, Glick RD, Huang J, et al. Cyclooxygenase 2 mediates the antiangiogenic effect of rapamycin in Ewing sarcoma. J Pediatr Surg 2009;44:1139-46.
26. Javelaud D, Besançon F. NF-kappa B activation results in rapid inactivation of JNK in TNF alpha-treated Ewing sarcoma cells: a mechanism for the anti-apoptotic effect of NF-kappa B. Oncogene 2001;20:4365-72.
27. Javelaud D, Poupon MF, Wietzerbin J, et al. Inhibition of constitutive NF-kappa B activity suppresses tumorigenicity of Ewing sarcoma EW7 cells. Int J Cancer 2002;98:193-8.
28. Lu G, Punj V, Chaudhary PM. Proteasome inhibitor Bortezomib induces cell cycle arrest and apoptosis in cell lines derived from Ewing's sarcoma family of tumors and synergizes with TRAIL. Cancer Biol Ther 2008;7:603-8.
29. Miao J, Kusafuka T, Fukuzawa M. Hotspot mutations of BRAF gene are not associated with pediatric solid neoplasms. Oncol Rep 2004;12:1269-72.
30. Reddy K, Cao Y, Zhou Z, et al. VEGF165 expression in the tumor microenvironment influences the differentiation of bone marrow-derived pericytes that contribute to the Ewing's sarcoma vasculature. Angiogenesis 2008;11:257-67.
31. Zhou Z, Bolontrade MF, Reddy K, et al. Suppression of Ewing's sarcoma tumor growth, tumor vessel formation, and vasculogenesis following anti vascular endothelial growth factor receptor-2 therapy. Clin Cancer Res 2007;13:4867-73.
32. Nagano A, Ohno T, Shimizu K, et al. EWS/Fli-1 chimeric fusion gene upregulates vascular endothelial growth factor-A. Int J Cancer 2010;126:2790-8.
33. Dalal S, Berry AM, Cullinane CJ, et al. Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family. Clin Cancer Res 2005;11:2364-78.
34. Yudoh K, Kanamori M, Ohmori K, et al. Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas. Br J Cancer 2001;84:1610-5.
35. Fuchs B, Inwards CY, Janknecht R. Vascular endothelial growth factor expression is up-regulated by EWS-ETS oncoproteins and Sp1 and may represent an independent predictor of survival in Ewing's sarcoma. Clinical Cancer Res 2004;10:1344-53.
36. Kreuter M, Paulussen M, Boeckeler J, et al. Clinical significance of vascular endothelial growth factor-A expression in Ewing's sarcoma. Eur J Cancer 2006;42:1904-11.
37. Dobashi Y, Suzuki S, Sato E, et al. EGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors. Mod Pathol 2009;22:1328-40.
38. McAllister NR, Lessnick SL. The potential for molecular therapeutic targets in Ewing's sarcoma. Curr Treat Options Oncol 2005;6:461-71.